Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Fairlie

Showing results (231-240 of 326) with videos related to

Pageof 33
Sort By:
Disease Models & Mechanisms|May 23, 2018
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasisSoo-Hyun Kim, Richard P Redvers, Lap Hing Chi, et al.
Immunology and Cell Biology|July 21, 2020
Lipopolysaccharide promotes Drp1-dependent mitochondrial fission and associated inflammatory responses in macrophagesRonan Kapetanovic, Syeda Farhana Afroz, Divya Ramnath, et al.
Antimicrobial Agents and Chemotherapy|January 4, 2019
Structure-Activity Relationships of Wollamide Cyclic Hexapeptides with Activity against Drug-Resistant and Intracellular <i>Mycobacterium tuberculosis</i>Zeinab G Khalil, Timothy A Hill, Luis M De Leon Rodriguez, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2025
Genome of venomous caterpillar <i>Doratifera vulnerans</i> reveals recruitment of immune peptides and their adaptation as pain-inducing toxinsMohaddeseh H Goudarzi, Samuel D Robinson, Fernanda C Cardoso, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2014
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficientsConan K Wang, Susan E Northfield, Barbara Colless, et al.
Scientific Reports|April 21, 2016
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonistsVernon Seow, Junxian Lim, Adam J Cotterell, et al.
Frontiers in Immunology|February 27, 2023
Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activationCaroline L Ashley, Brian P McSharry, Hamish E G McWilliam, et al.
Nephrology (Carlton, Vic.)|July 18, 2019
Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidneyFrank Y Ma, Yingjie Han, Elyce Ozols, et al.
Nature Immunology|April 5, 2016
The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1Hamish E G McWilliam, Sidonia B G Eckle, Alex Theodossis, et al.
Molecular Pharmacology|March 27, 2004
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activityDarren R March, Lavinia M Proctor, Martin J Stoermer, et al.
Pageof 33

Showing results (231-240 of 326) with videos related to

Sort By:
Pageof 33
Disease Models & Mechanisms|May 23, 2018
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasisSoo-Hyun Kim, Richard P Redvers, Lap Hing Chi, et al.
Immunology and Cell Biology|July 21, 2020
Lipopolysaccharide promotes Drp1-dependent mitochondrial fission and associated inflammatory responses in macrophagesRonan Kapetanovic, Syeda Farhana Afroz, Divya Ramnath, et al.
Antimicrobial Agents and Chemotherapy|January 4, 2019
Structure-Activity Relationships of Wollamide Cyclic Hexapeptides with Activity against Drug-Resistant and Intracellular <i>Mycobacterium tuberculosis</i>Zeinab G Khalil, Timothy A Hill, Luis M De Leon Rodriguez, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2025
Genome of venomous caterpillar <i>Doratifera vulnerans</i> reveals recruitment of immune peptides and their adaptation as pain-inducing toxinsMohaddeseh H Goudarzi, Samuel D Robinson, Fernanda C Cardoso, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2014
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficientsConan K Wang, Susan E Northfield, Barbara Colless, et al.
Scientific Reports|April 21, 2016
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonistsVernon Seow, Junxian Lim, Adam J Cotterell, et al.
Frontiers in Immunology|February 27, 2023
Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activationCaroline L Ashley, Brian P McSharry, Hamish E G McWilliam, et al.
Nephrology (Carlton, Vic.)|July 18, 2019
Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidneyFrank Y Ma, Yingjie Han, Elyce Ozols, et al.
Nature Immunology|April 5, 2016
The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1Hamish E G McWilliam, Sidonia B G Eckle, Alex Theodossis, et al.
Molecular Pharmacology|March 27, 2004
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activityDarren R March, Lavinia M Proctor, Martin J Stoermer, et al.
Pageof 33